jRCTs031180130已完成不适用
Phase II study of primary treatment by FOLFOXIRI+bevacizumab in patients with RAS mutant-type metastatic colorectal cancer (JACCRO CC-11 )
未提供0 个研究点目标入组 60 人开始时间: 2015年2月18日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 20age old over 至 76age old not（—）
- 性别
- All
入选标准
- •(1) Histologically confirmed colorectal cancer. (2) KRAS mutant-type, or RAS mutant-type. (3) Measurable leision by RECIST(Ver.1.1) (4) No past history of chemotherapy in the case of unresectable primary lesion/distant metastasis/lymph node metastasis.In the case of recurrence, no treatment for the first recurrence leision after operation. (5) Age; more than 20 years old, under 76 years old. (6) ECOG Performance status 0-1.The case >=71 years is PS
- •(7) Life expectancy of more than 3 months. (8) Patiens have enough organ function for study treatment within 14 days before enrollment; 1) WBC>=3,000/mm3, <12,000/mm
- •Neu>=1,500/mm
- •PLT>=10.0x104/mm
- •Hb>=9.0g/dL. 5) Total Bilirubin<=1.5xULN. 6) AST<=2.5xULN. 7) ALT<=2.5xULN. 8) Creatinine<=1.5xULN. 9) Proteinuria<=1+. 10) PT-INR<=1.
- •(9) Written informed consent.
排除标准
- •(1) Synchronous multiple malignancy or metachronous multiple malignancy within 5 years disease free interval. (2) Brain metastases. (3) Infectious disease. (4) Interstitial lung disease or pulmonary fibrosis. (5) Comorbidity or history of serious heart failure. (6) History of thromboembolic events. (7) Cerebrovascular disease. (8) History of hemoptysis/hematemesis. (9) Uncontrolled hypertension.(systolic BP>180mmHg, or diastolic BP>100mmHg) (10) Sensory alteration or paresthesia interfering with function. (11) Large quantity of pleural, abdominal or cardiac effusion. (12) Severe comorbidity (renal failure, liver failure, hypertension, etc) (13) Prior radiotherapy for primary and metastases leision. (14) Men/women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test. (15) History of severe allergy. (16) HBs-Ag(+), or HCV-Ab(+). (17) Administration of blood products/ G-CSF, and blood transfusion within 14 days. (18) Surgical procedure or such as skin-open biopy, trauma surgery, or other more intensive surgeries within 28 days. (19) Systemaic administration of antiplatelet drug or NSAIDs. (20) Diathesis of bleeding (history of hemoptysis, including cavitation and/or necrosis in lung metastasis confirmed by imaging), coagulopathy. (21) Active peptic ulcer. (22) History of gastrointestinal perforation within 1 year. (23) Unhealed traumatic bone fracture. (24) Uncontrolled diarrhea. (25) History of organ recipient . (26) Prior bevacizumab/Irinotecan/Oxaliplatin treatment.(Adjuvant therapy by Oxaliplatin is excluded) (27) Administration of atazanavir sulfate. (28) Jaundice. (29) Ileus or bowel obstruction. (30) Any other cases who are regarded as inadequate for study enrollment by investigators.
结局指标
主要结局
-
Response Rate
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
JBCRG-C11(CREA)HER2-positive advanced or metastatic breast cancerjRCT1031240010DAIICHI SANKYO COMPANY, LIMITED100
进行中（未招募）
不适用
C-PROWESS study (C-PROWESS study)Neo Ras Wild type metastatic colorectal cancerjRCTs03121056530
招募中
不适用
ACE study (ACE study)Gastric adenoma or early gastric cancer that is an absolute indication for ESD.jRCT103224050764
已完成
不适用
Lucent-J Study (Lucent-J Study)Type 2 diabetes mellitusjRCTs05122001640
招募中
不适用
JBCRG-M10 (INDUCE trial)PD-L1-positive, hormone receptor-negative, HER2-negative inoperable or recurrent breast cancerjRCTs041240039106